Davis Polk advised the sales agent on the SEC-registered at-the-market offering by IDEAYA Biosciences, Inc. of its common stock for up to an aggregate amount of $90 million.
Based in South San Francisco, California, IDEAYA is a clinical stage oncology-focused precision medicine company developing targeted therapeutics for patients selected using molecular diagnostics across multiple oncology indications.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye and Lawrence Traylor Jr. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.